David Happel's Net Worth
$2.02 Million
Who is David Happel?
David Happel has an estimated net worth of $2.02 Million. This is based on reported shares across multiple companies, which include Horizon Pharma plc, Sagimet Biosciences Inc., and Raptor Pharmaceutical Corp.
SEC CIK
David Happel's CIK is 0001623567
Past Insider Trading and Trends
2023 was David Happel's most active year for acquiring shares with 4 total transactions. David Happel's most active month to acquire stocks was the month of January. 2016 was David Happel's most active year for disposing of shares, totalling 4 transactions. David Happel's most active month to dispose stocks was the month of September. 2024 saw David Happel paying a total of $63,730.70 for 12,100 shares, this is the most they've acquired in one year. In 2016 David Happel cashed out on 132,233 shares for a total of $342,834.41, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Horizon Pharma plc No price found
EVP, Commercial Dev & StrategyDavid Happel owns 5,089 units of Ordinary Shares. In the year 2016 David Happel acquired a total of 7,953 shares in Horizon Pharma plc, David also disposed a total of 4,150 shares of Horizon Pharma plc equalling to $56,149.50.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +295.72% | 3.8K |
$13.53 | -$56,149.50 | 5.09K |
Oct 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Sagimet Biosciences Inc. (SGMT) Snapshot price: $2.65
President & CEODavid Happel owns 639,200 units of Series A Common Stock which is worth $1,693,880.00. In the year 2023 David Happel acquired a total of 639,200 shares in Sagimet Biosciences Inc. at a cost of $71,677.20.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +1.93% | 12.1K |
$5.27 | $63,730.70 | 639.2K |
Mar 26
| |||
Form 4
| +0.26% | 1.6K |
$4.10 | $6,560.00 | 627.1K |
Dec 7
| |||
Form 4
| +105,916.95% | 624.91K |
—
|
—
| 625.5K |
Nov 17
| |||
Form 4
|
∞
| 590 |
$2.35 | $1,386.50 | 590 |
Nov 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Raptor Pharmaceutical Corp No price found
Chief Commercial OfficerDavid Happel used to own units in Common Stock but no longer holds any shares there. From 2014 to 2016 David Happel acquired a total of 30,246 shares in Raptor Pharmaceutical Corp, David also disposed a total of 38,449 shares of Raptor Pharmaceutical Corp equalling to $342,834.41.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -37.87K |
$9.00 | -$340,857.00 |
0
|
Oct 24 - Oct 25
| |||
Form 4
| -1.90% | -576.00 |
$3.43 | -$1,977.41 | 29.67K |
Mar 1
| |||
Form 4
| +478.43% | 25.02K |
—
|
—
| 30.25K |
Feb 9
| |||
Form 4
|
∞
| 5.23K |
—
|
—
| 5.23K |
Feb 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||